About Us

Restart Life Sciences is at the forefront of developing natural remedies specifically tailored for individuals on the autism spectrum. Our focus is on creating innovative health foods  that address the unique needs of this community. Recognizing the significant gap in the marketplace for effective, natural solutions, we are committed to creating high-quality products that promote overall wellness and support healthier lifestyles.

Restart Life Sciences is dedicated to developing health-related foods that promote both mind and body wellness for healthy living. Our mission is to create innovative, nutrient-rich products that support mental clarity, physical vitality, and overall well-being. By focusing on holistic nutrition, we aim to empower individuals to lead healthier, more balanced lives. Join us as we explore the intersection of nutrition and wellness, paving the way for a brighter future.

Restart Life Sciences secured a production agreement with a co-packer, a recognized leader in the health food industry, who will serve as the official production partner for the Brain Balls and subsequent product lines. The co-packer operates a fully equipped production facility in British Columbia, Canada, which will be utilized to handle raw ingredients, package and ship, ensuring the highest quality standards for consumers.

The co-packer, known for its flagship branded healthy cereals, has demonstrated a proven track record of success in the production and distribution of health-conscious, clean-label food products. Their production capabilities, combined with their expertise in delivering high-quality products, make them an ideal partner for Restart Life.

The co-packers' expertise will ensure that the Brain Balls product line is produced in a facility that meets the highest standards of quality and safety. This partnership also opens up exciting opportunities to further expand distribution to new markets, both in Canada and abroad.

Restart Life Sciences and Brain Balls have entered into a Joint Venture to advance Brain Balls' innovative cognitive health products. The collaboration will initially focus on developing all-natural solutions targeting ADHD, autism, and other cognitive disorders. These products will be made available through digital marketplaces, ensuring easy access for consumers seeking effective, trusted health solutions. The joint venture highlights both companies' shared dedication to prioritizing consumer well-being and delivering results-driven wellness products.

We are partnered with KGK Science to conduct the Phase IIA clinical trial which is being carried out at the KGK facility in London, Ontario, Canada. This 10-person, open-label study will assess repetitive, oral low-dose psilocybin therapy for FXS. The Company intends to confirm changes in behavioural symptoms with state-of-the-art diagnostic and therapeutic mRNA and serotonin biomarker technology, combined with machine learning artificial intelligence (AI).

Under the terms of the agreement, in consideration of the assignment of the property (Intellectual property and patent of the mRNA neuro panel and serotonin assay, along with any and all data accumulated testing these assays), Ludwig issue to the company 750,000 restricted shares of its common stock. In addition, for a period of 10 years from the date of the agreement, Ludwig shall pay the company a 2.5-per-cent royalty on all revenue derived from the commercialization of the property up to the amount of $245,712 (U.S.) and 5 per cent on any revenue over this amount.